Ligachem Bioscience Officially Invited to Participate in the 44th J.P. Morgan Healthcare Conference

Ligachem Bioscience announced on January 6 that it has been officially invited to participate in the 44th J.P. Morgan Healthcare Conference 2026, the world’s largest pharmaceutical and biotech investment event, which will be held in San Francisco, United States, from January 12 to 15 (local time).

At this conference, Ligachem Bioscience, as an officially invited company, plans to introduce its proprietary ADC (Antibody-Drug Conjugate) platform and new drug candidates to global pharmaceutical giants and engage in discussions regarding technology transfer. In particular, the core focus of this participation is to further deepen partnership discussions with pharmaceutical companies worldwide, leveraging the proven technological capabilities of Ligachem Bioscience’s ADC platform, “ConjuAll,” whose pipeline has recently achieved significant results in global clinical trials.

Recently, Ligachem Bioscience has garnered global attention as clinical data from its major out-licensed pipelines have been successfully confirmed one after another. Notably, the HER2 (human epidermal growth factor receptor 2)-targeted ADC “IKS014 (LCB14)” demonstrated excellent efficacy and safety in its global Phase 1 clinical trial, as well as the potential for “post-Enhertu” applications, which is currently a key topic in the field of HER2-targeted ADCs. Additionally, the ROR1-targeted ADC “CS5001 (LCB71)” became the first ROR1 ADC to demonstrate efficacy not only in hematologic cancers but also in solid tumors, confirming its superiority in both efficacy and safety compared to competing drugs under development.

On the strength of these achievements, inquiries from global companies seeking to adopt ADC platform technology and new drug candidates have increased significantly compared to last year. Accordingly, during the event, Ligachem Bioscience plans to hold in-depth follow-up meetings with existing potential partners, as well as actively pursue partnership discussions with new major pharmaceutical companies interested in adopting the platform.

Through these meetings, Ligachem Bioscience intends to actively promote the value of its next-generation ADC linkers and proprietary payloads. In particular, this time, the company will highlight the competitiveness of its proprietary payload technology, “PBD prodrug,” as well as the value of newly developed ADC linkers and payloads, such as the “next-generation Topo1i payload,” which overcomes resistance issues associated with current commercialized or clinical-stage “Topoisomerase I inhibitor (Topo1i)” payloads. As competition for leadership in the global ADC market intensifies, Ligachem Bioscience’s validated platform technology is being recognized as an attractive option by many potential partners.

Park Sejin, Chief Operating Officer (COO) of Ligachem Bioscience, stated, “Through our participation in this year’s J.P. Morgan Healthcare Conference, we will prove that Ligachem Bioscience’s technological capabilities are now firmly recognized as a global standard, rather than merely being a source of anticipation. With the platform’s credibility maximized by a series of positive clinical data, we will do our utmost to accelerate ongoing technology transfer discussions and achieve tangible results through this conference.”